Pfizer, BioNTech to develop 1st mRNA vaccine for shingles

Pfizer and BioNTech are collaborating to create a new mRNA vaccine, this time for shingles.

The shingles project is the third vaccine collaboration between the two companies, as they began an influenza vaccine collaboration in 2018 and a COVID-19 vaccine collaboration in 2020, according to a Jan. 5 news release.

The vaccine will be based on BioNTech’s mRNA platform and Pfizer’s antigen technology, the companies said. Under the deal, Pfizer will pay BioNTech $225 million and BioNTech will pay Pfizer $25 million.

The companies expect clinical trials to begin in the second half of 2022.

Read more about the collaboration here.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like